Head to Head Review: AtriCure (ATRC) versus Its Peers
AtriCure (NASDAQ: ATRC) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its peers? We will compare AtriCure to similar businesses based on the strength of its earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and dividends.
Valuation and Earnings
This table compares AtriCure and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|AtriCure||$166.00 million||-$19.62 million||-22.98|
|AtriCure Competitors||$827.23 million||$159.49 million||36.41|
AtriCure’s peers have higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
AtriCure has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, AtriCure’s peers have a beta of 1.06, meaning that their average share price is 6% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for AtriCure and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AtriCure currently has a consensus target price of $24.83, indicating a potential upside of 6.99%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.41%. Given AtriCure’s stronger consensus rating and higher probable upside, analysts clearly believe AtriCure is more favorable than its peers.
This table compares AtriCure and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
82.1% of AtriCure shares are owned by institutional investors. Comparatively, 63.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 10.0% of AtriCure shares are owned by company insiders. Comparatively, 12.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA).
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.